Collegium Pharmaceutical (COLL) Total Current Liabilities (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Total Current Liabilities of $435.0 million for Q1 2026, down 10.63% year-over-year from $486.7 million in Q1 2025, and down 1.15% quarter-over-quarter from $440.0 million in Q4 2025.
Collegium Pharmaceutical (COLL) Total Current Liabilities (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Total Current Liabilities history runs 13 years deep, the most recent figure standing at $435.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 10.63% year-over-year to $435.0 million; the TTM figure through Mar 2026 stood at $435.0 million (down 10.63% YoY), while the FY2025 annual figure was $440.0 million, down 13.64% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $435.0 million, down from $440.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $509.5 million in Q4 2024, with the low at $373.6 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $446.4 million (2024), against an average of $444.9 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 82.99% in 2022, then declined 13.64% in 2025.
- Collegium Pharmaceutical's Total Current Liabilities stood at $433.7 million in 2022, then rose by 5.58% to $457.9 million in 2023, then advanced by 11.27% to $509.5 million in 2024, then slipped by 13.64% to $440.0 million in 2025, then declined by 1.15% to $435.0 million in 2026.
- Business Quant data shows COLL's Total Current Liabilities at $435.0 million in Q1 2026, $440.0 million in Q4 2025, and $452.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.79 Bn |
| 10 | Collegium Pharmaceutical | 889.75 Mn | 740.43 Mn | 110.29 Mn | 589.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 589.86 Mn |
| Mar 31, 2026 | 434.97 Mn |
| Dec 31, 2025 | 440.03 Mn |
| Sep 30, 2025 | 452.93 Mn |
| Jun 30, 2025 | 464.61 Mn |
| Mar 31, 2025 | 486.71 Mn |
| Dec 31, 2024 | 509.51 Mn |
| Sep 30, 2024 | 459.43 Mn |
| Jun 30, 2024 | 461.72 Mn |
| Mar 31, 2024 | 446.44 Mn |
| Dec 31, 2023 | 457.92 Mn |
| Sep 30, 2023 | 464.61 Mn |
| Jun 30, 2023 | 435.06 Mn |
| Mar 31, 2023 | 412.70 Mn |
| Dec 31, 2022 | 433.73 Mn |
| Sep 30, 2022 | 414.50 Mn |
| Jun 30, 2022 | 415.09 Mn |
| Mar 31, 2022 | 373.57 Mn |
| Dec 31, 2021 | 279.57 Mn |
| Sep 30, 2021 | 268.97 Mn |